Table 2.

Univariate Analyses in the Discovery Cohort

Variable		Complete Response, CR (N = 185)		Overall Survival, OS (N = 185)		Relapse-Free Survival, RFS (N = 106)
		OR (95% CI)	P	HR (95% CI)	P	HR (95% CI)	P
Age	Continuous	0.96 (0.94–0.98)	< 0.001	1.06 (1.04–1.07)	< 0.001	1.04 (1.02–1.05)	< 0.001
	By Decade	0.66 (0.53–0.82)	< 0.001	1.75 (1.52–2.01)	< 0.001	1.41 (1.20–1.67)	< 0.001
Cytogenetics	Fav. vs. Interm.	5.29 (1.15–24.40)	0.033*	0.24 (0.10–0.59)	0.002*	0.29 (0.12–0.69)	0.005*
	Unfav. vs. Interm.	0.42 (0.18–0.97)	0.043*	1.77 (1.12–2.79)	0.014*	1.38 (0.71–2.68)	0.349*
	Unk. vs. Interm.	0.57 (0.28–1.16)	0.124*	1.25 (0.84–1.88)	0.271*	0.80 (0.46–1.41)	0.446*
Performance Status	Numeric	0.82 (0.58–1.15)	0.246	1.07 (0.89–1.30)	0.462	0.84 (0.62–1.15)	0.278
	2–3 vs. 0–1	0.37 (0.17–0.81)	0.013	1.49 (0.97–2.29)	0.07	1.01 (0.50–2.03)	0.971
Study	S0106 vs S9031	2.88 (1.20–6.87)	0.018*	0.28 (0.17–0.46)	< 0.001*	0.35 (0.18–0.69)	0.002*
	S9333 vs S9031	1.04 (0.40–2.73)	0.934*	0.87 (0.53–1.43)	0.58*	0.79 (0.38–1.67)	0.54*
	S0112 vs S9031	0.63 (0.17–2.33)	0.484*	1.16 (0.61–2.22)	0.645*	0.79 (0.27–2.30)	0.669*
Immunophenotype	2 vs 0	1.37 (0.68–2.75)	0.384	1.14 (0.77–1.70)	0.504	1.26 (0.76–2.08)	0.373
	1 vs 0	0.73 (0.33–1.57)	0.415	1.02 (0.64–1.61)	0.946	0.97 (0.51–1.86)	0.928
AML Onset	Secondary vs. DN	0.23 (0.08–0.67)	0.007	1.89 (1.10–3.25)	0.02	0.95 (0.30–3.01)	0.925
ELN2017 in MNCs	Fav. vs. Interm.	3.11 (1.16–8.32)	0.024*	0.58 (0.32–1.02)	0.06*	0.47 (0.24–0.92)	0.027*
	Adv. vs. Interm.	0.64 (0.27–1.56)	0.328*	1.66 (1.00–2.77)	0.05*	1.72 (0.88–3.35)	0.113*
	Unk. vs. Interm.	0.72 (0.29–1.75)	0.467*	1.32 (0.78–2.23)	0.305*	0.76 (0.37–1.54)	0.441*
ELN2017 in VLBs	Fav. vs. Interm.	3.69 (1.30–10.52)	0.014*	0.38 (0.21–0.68)	0.001*	0.37 (0.18–0.77)	0.008*
	Adv. vs. Interm.	0.77 (0.30–1.98)	0.587*	1.10 (0.66–1.84)	0.72*	1.45 (0.71–2.97)	0.312*
	Unk. vs. Interm.	0.96 (0.37–2.47)	0.928*	0.78 (0.46–1.33)	0.36*	0.64 (0.31–1.35)	0.242*

* Indicates that the overall p-value was significant (< 0.05)